S-1/A: BioVie Inc. Files Amended Prospectus for $15 Million Public Offering Amidst Clinical Trial Setbacks and Going Concern Warning

BioVie Inc., a clinical-stage biopharmaceutical company, has filed an amended S-1 registration statement for a public offering of units to raise approximately $13.5 million, as it navigates significant clinical trial protocol violations for its Alzheimer's drug candidate and addresses a 'going concern' doubt from its auditors.

Summary

• BioVie Inc. is a clinical-stage biopharmaceutical company focused on neurological and neurodegenerative disorders (Alzheimer's, Parkinson's, Long COVID) and advanced liver disease (ascites).
• The company is offering 1,456,310 units, each consisting of one share of Class A Common Stock and one warrant, at an assumed public offering price of $10.30 per unit, aiming to raise approximately $13.5 million in net proceeds.
• An additional 1,456,310 pre-funded units are also being offered, consisting of one pre-funded warrant and one common warrant, primarily for purchasers who would exceed beneficial ownership limits.
• The company's Alzheimer's disease (AD) Phase 3 clinical trial (NCT04669028) for bezisterim (NE3107) experienced significant protocol deviations and cGCP violations at 15 study sites, leading to patient exclusions and leaving the trial underpowered for its primary endpoints.
• Despite exclusions, a preliminary signal of efficacy was detected in the Per-Protocol population, suggesting a slowing of cognitive loss and an advantage in age deceleration.
• A new Phase 2b study of bezisterim for new onset Parkinson's disease (PD) commenced in April 2025, following FDA approval of the protocol in July 2024.
• A Phase 2 ADDRESS-LC study of bezisterim for neurological symptoms associated with Long COVID commenced in May 2025, fully funded by a $13.1 million grant from the U.S. Department of Defense (DOD).
• For its liver cirrhosis program, BioVie is finalizing the protocol design for a Phase 3 study of BIV201 (continuous infusion terlipressin) for patients with cirrhosis and ascites who recently recovered from acute kidney injury (AKI), after receiving FDA guidance in June 2023 and December 2024.
• Phase 2 data for BIV201 in refractory ascites showed a 30% reduction in ascites fluid during treatment and a 53% reduction in patients who completed treatment, sustained at 43% reduction over three months post-treatment.
• The company reported a net loss of approximately $2.8 million for the three months ended March 31, 2025, a decrease from $8.1 million for the same period in 2024, primarily due to decreased R&D expenses.
• For the nine months ended March 31, 2025, the net loss was approximately $14.1 million, down from $27.2 million in the prior year, driven by a $13.0 million reduction in R&D expenses.
• As of March 31, 2025, BioVie had working capital of approximately $21.2 million and cash and cash equivalents totaling approximately $23.2 million, but its auditors have raised substantial doubt about its ability to continue as a going concern.
• The company's common stock underwent a 1-for-10 reverse stock split effective July 7, 2025, approved by the Board on June 26, 2025, to maintain Nasdaq listing compliance.
• BioVie is currently subject to a securities class action lawsuit and two shareholder derivative lawsuits alleging material misrepresentations related to the AD Phase 3 study, with a motion to dismiss denied on March 27, 2025, allowing the case to proceed to fact discovery.

Sentiment

Score: 3

Explanation: The sentiment is low due to significant clinical trial integrity issues (AD Phase 3), persistent net losses, negative cash flow from operations, and the auditor's 'going concern' warning. While there are positive developments in other programs and recent capital raises, the fundamental challenges and legal proceedings create substantial uncertainty and risk for investors.

Positives

• Received a clinical trial grant of up to $13.1 million from the U.S. Department of Defense (DOD) for the Long COVID program, providing non-dilutive funding.
• FDA authorized the Investigational New Drug (IND) application for bezisterim in Long COVID, allowing the study to proceed.
• Phase 2 study of bezisterim in Parkinson's disease showed significant improvements in morning on symptoms and clinically meaningful improvement in motor control, with no drug-related adverse events.
• BIV201 (continuous infusion terlipressin) was granted FDA Fast Track designation and Orphan Drug Status for ascites and hepatorenal syndrome, indicating recognition of unmet medical need.
• Phase 2 data for BIV201 in refractory ascites showed promising results, with a 30% to 53% reduction in ascites fluid accumulation.
• Proprietary liquid formulation of BIV201 offers room temperature stability for up to two years, a key product differentiation compared to other terlipressin products requiring refrigeration.
• Patents for BIV201's novel liquid formulation have been granted in the U.S., China, Japan, Chile, and India.
• Net loss decreased by $5.3 million for the three months ended March 31, 2025, and by $13.1 million for the nine months ended March 31, 2025, primarily due to reduced R&D expenses.

Negatives

• The Phase 3 Alzheimer's disease trial for bezisterim was significantly underpowered for its primary endpoints due to 'significant deviation from protocol and current good clinical practices (cGCPs) violations' at 15 study sites, leading to patient exclusions and referral to the FDA Office of Scientific Investigations (OSI).
• The company has no products approved for commercial sale and has never generated any revenues, raising substantial doubt about its ability to continue as a going concern.
• The company will need to raise substantial additional capital in the future to fund operations, and there is no assurance that sufficient financing will be obtained on acceptable terms, if at all.
• The company is currently subject to securities class action litigation and two shareholder derivative lawsuits, which will require significant management time and attention, result in substantial legal expenses, and could lead to unfavorable outcomes.
• The Reverse Stock Split has caused and could further cause the stock price to decline relative to its value before the split and decrease the liquidity of shares.
• There is no established public trading market for the Pre-funded Warrants or Warrants being offered, and the company does not expect a market to develop for the Pre-funded Warrants, limiting liquidity for investors.

Risks

• Reliance on third-party contractors for clinical trials, with potential for failure to carry out duties, meet deadlines, or comply with regulatory requirements, leading to delays or inability to obtain regulatory approval.
• High uncertainty in successful biopharmaceutical development, with product candidates potentially failing in later stages due to ineffectiveness, harmful side effects, or regulatory delays/refusals.
• Concentration of assets within certain financial institutions in excess of federally insured levels, posing a risk of liquidity constraints or inability to access cash if bank failures or financial instability concerns arise.
• Ongoing securities class action litigation and potential future litigation requiring significant management time and attention, resulting in substantial legal expenses, and potentially leading to unfavorable outcomes or fines.
• No products approved for commercial sale and no revenues generated to date, with no assurance of achieving revenues or profitability, which could lead to cessation of operations.
• Limited operating history as a development stage company, making business and investment evaluation difficult, and raising substantial doubt about the ability to continue as a going concern.
• Risk of FDA or comparable foreign regulatory authorities approving generic versions of product candidates, or not granting sufficient exclusivity periods, adversely affecting product sales.
• Failure to obtain or maintain Orphan Drug exclusivity for BIV201, potentially reducing the length of time to prevent competitors from selling generic versions.
• Limited experience in drug development, potentially leading to inability to successfully develop any drugs and cessation of operations.
• Development of pharmaceutical products is a time-consuming process with many factors outside of control, potentially delaying or preventing commercialization.
• Risk of expending limited resources on a particular drug candidate or indication that may not be profitable or have a high likelihood of success, missing other opportunities.
• No manufacturing experience, relying on Contract Manufacturing Organizations (CMOs), with risks of non-compliance with regulations (cGMP) or inability to secure adequate supplies.
• Lack of sales and marketing personnel, requiring reliance on others or inability to generate sales without hiring and retaining such staff.
• Need to comply with significant and complex government regulations, which may delay or prevent commercialization.
• Potential business disruption and related risks from future pandemics.
• Loss or unavailability of key management personnel could put the company at a competitive disadvantage.
• Inability to attract and retain highly skilled personnel due to competition.
• Inability to compete with larger, better-resourced enterprises in the highly competitive biotechnology and biopharmaceutical industries.
• Potential conflicts of interest among officers, directors, and stockholders due to other business activities and economic interests.
• Inability to obtain or protect intellectual property rights, leading to loss of competitive advantage or substantial litigation costs.
• Risk of patent terms being inadequate to establish a competitive position for drug candidates for a sufficient time.
• Inability to protect intellectual property rights globally, as foreign laws may offer less protection.
• Changes in patent law potentially diminishing the value of patents and impairing protection ability.
• Involvement in lawsuits to protect or enforce patents, which could be expensive, time-consuming, and unsuccessful, with patents potentially found invalid or unenforceable.
• Failure to identify relevant third-party patents or incorrect interpretation of their scope/expiration, leading to infringement claims.
• Claims by third parties asserting infringement, misappropriation, or violation of their intellectual property rights.
• Claims challenging the inventorship of patents and other intellectual property.
• Intellectual property rights not addressing all potential threats, such as independent development by competitors.
• Intellectual property litigation leading to unfavorable publicity and stock price decline.
• Immediate and substantial dilution in net tangible book value per share for new investors in the offering.
• Management having broad discretion over the use of net proceeds, potentially investing them in ways with which investors may not agree or that may not yield significant returns.
• Stock price volatility, with no assurance of reselling common stock at or above the purchase price.
• Nasdaq potentially delisting common stock if the offering does not qualify as a public offering under stockholder approval rules.
• No intention to pay dividends on common stock, limiting returns to stock price appreciation.
• Future dilution from additional equity offerings or issuance of shares subject to options, warrants, or other arrangements.
• Limited trading market for common stock, making it difficult to liquidate investments in a timely manner.
• No established public trading market for Pre-funded Warrants or Warrants, and no expectation of a market developing for Pre-funded Warrants.
• Speculative nature of Pre-funded Warrants and Warrants, with no assurance of profitability upon exercise.
• Risk that Warrants and Pre-funded Warrants may have no value in bankruptcy or reorganization proceedings.
• Reverse Stock Split causing and potentially further causing stock price decline and decreased liquidity.
• Failure to maintain effective internal control over financial reporting, potentially harming the company and stock price.
• Lack of public company experience of management team, potentially impacting compliance with U.S. securities laws.
• Status as a smaller reporting company, potentially making stock less attractive to investors due to scaled disclosure requirements.
• Incurrence of audit and legal fees due to periodic reporting requirements, negatively affecting profitability.
• Authorization to issue blank check preferred stock without stockholder approval, potentially adversely impacting rights of common stockholders.
• Anti-takeover provisions in Articles of Incorporation, Bylaws, and Nevada law, potentially discouraging or delaying changes in control or management.

Future Outlook

BioVie Inc. anticipates continuing its clinical development programs for bezisterim in Parkinson's disease and Long COVID, with trials having recently commenced. The company is also finalizing the protocol design for a Phase 3 study of BIV201 for liver cirrhosis and ascites. Future operations are dependent on securing additional financing, as the company has not generated revenue and expects to finance needs through equity offerings, debt, or collaborations. Management will have broad discretion over the use of proceeds from the current offering, which are intended for working capital and general corporate purposes.

Management Comments

• Management expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions.
• Management believes that the claims in the securities class action lawsuit are without merit and intends to defend vigorously against them.

Industry Context

BioVie operates in the highly competitive biotechnology and biopharmaceutical industries, characterized by rapid technological developments. The company faces competition from well-established and well-capitalized firms, including major pharmaceutical companies applying biotechnology. While there are no FDA-approved drugs specifically for ascites due to liver cirrhosis, other companies are developing therapies for severe complications of advanced liver cirrhosis (e.g., Ocelot Bio) that could indirectly or directly compete with BIV201. Similarly, in Alzheimer's and Parkinson's diseases, companies like Biogen and Eli Lilly are developing treatments that could compete with bezisterim. The success of new therapies depends on efficacy, safety, reliability, availability, price, and patent protection, as well as the speed of development and market introduction.

Comparison to Industry Standards

• The company's BIV201 (continuous infusion terlipressin) offers a novel room temperature stable formulation in a pre-filled syringe, which is a key product differentiation compared to other terlipressin products globally that require refrigeration and are not available in prefilled syringe format.
• Mallinckrodt Hospital Products IP Limited gained FDA approval in September 2022 for its lyophilized terlipressin acetate for bolus intravenous administration for hepatorenal syndrome Type 1, which is a competing product in a related indication to BIV201.
• Ferring Pharmaceuticals Inc. received Orphan Drug designation in 1986 for terlipressin for the treatment of bleeding esophageal varices, indicating other companies have long-standing involvement with terlipressin.
• The AD Phase 3 trial for bezisterim was originally designed to be 80% powered with 125 patients in each arm, but the unplanned exclusion of 15 sites (virtually all from one geographic area) due to cGCP violations left the trial underpowered, which is a significant deviation from standard clinical trial execution and data integrity expectations in the industry.

Management Changes

Corporate Governance

Legal Proceedings

• A purported shareholder class action complaint, Eric Olmstead v. BioVie Inc. et al., was filed on January 19, 2024, in the U.S. District Court for the District of Nevada, naming the company and certain officers as defendants.
• A second, related putative securities class action, Way v. BioVie Inc. et al., was filed on February 22, 2024, in the same court, asserting similar claims.
• On April 15, 2024, the court consolidated these two actions under In re BioVie Inc. Securities Litigation, No. 3:24-cv-00035.
• An amended complaint was filed on June 21, 2024, alleging material misrepresentations and/or omissions related to the NM101 Phase 3 study and trial of bezisterim (NE3107) in mild to moderate probable Alzheimer's Disease, in violation of Sections 10(b) and 20(a) of the Exchange Act, and Rule 10b-5.
• The class action covers purchasers of the company's securities during the period from December 7, 2022, through November 28, 2023, and seeks unspecified monetary damages, costs, and attorneys' fees.
• Defendants' motion to dismiss the amended complaint was denied on March 27, 2025, allowing the case to move into fact discovery.
• A shareholder derivative lawsuit, Andrew Hulm, was filed on December 30, 2024, in the U.S. District Court for the District of Nevada, piggy-backing on the securities class action and naming certain current and former officers and directors as defendants, alleging breach of fiduciary duties.
• A second shareholder derivative lawsuit, William Settel, was filed on April 28, 2025, in the U.S. District Court for the District of Nevada, also piggy-backing on the securities class action with similar claims.
• The company believes the claims are without merit and intends to defend vigorously, but the outcome is uncertain and could result in substantial damages or fines, with insurance coverage subject to a $2 million deductible.

Related Party Transactions

• The company acquired the biopharmaceutical assets of NeurMedix, Inc., a privately held clinical-stage pharmaceutical company and a related party, in June 2021.
• On July 15, 2022, the company entered into a securities purchase agreement with Acuitas Group Holdings, LLC (Acuitas), the company's largest stockholder, for a private placement of common stock and warrants.
• The down round feature of the PIPE Warrant Shares held by Acuitas resulted in deemed dividends of $886,423 for the year ended June 30, 2024, $325,041 for the three months ended September 30, 2024, and $44,424 for the three months ended December 31, 2024, due to subsequent stock sales at lower prices.
• During the nine months ended March 31, 2025, the company paid a Director $50,000 for consulting services.

Stakeholder Impact

• **Shareholders:** Will experience immediate and substantial dilution from the current offering. Existing shareholders will see a decrease in net tangible book value per share. Future equity offerings could cause further dilution. The recent 1-for-10 reverse stock split has already caused a decline in value and may decrease liquidity. The ongoing securities class action and derivative lawsuits pose a risk of substantial damages, which could negatively affect the stock price and financial condition.
• **Employees:** The company had a reduction in force in December 2023, impacting clinical team payroll. Stock options and restricted stock units are part of compensation, but their value is tied to the volatile stock price. The company sponsors a 401K plan with a 5% match.
• **Customers (Future):** Patients suffering from Alzheimer's, Parkinson's, Long COVID, and advanced liver disease (ascites) are the target beneficiaries of the company's drug candidates. The success or failure of clinical trials directly impacts the availability of new treatment options for these patient populations.
• **Suppliers/Vendors:** The company relies on third-party contractors (CROs, manufacturers, consultants) for clinical trials and drug production. Delays or failures by these parties could impact the company's operations. The company has awarded common stock to vendors for services.
• **Creditors:** The company's ability to continue as a going concern is dependent on securing additional financing, which is a risk for creditors. The company recently paid off a $15 million loan, reducing debt obligations.

Next Steps

• Finalize the actual public offering price per Unit with underwriters.
• Underwriters expect to deliver shares to purchasers on or about the specified date in 2025.
• Apply to list the Warrants on Nasdaq under the symbol BIVIW.
• Consider employing the adaptive trial feature of the AD Phase 3 protocol to continue enrolling patients to achieve statistical significance.
• Consider designing a new Phase 3 study of bezisterim (NE3107) for AD.
• Continue the new Phase 2b study of bezisterim for new onset Parkinson's disease, which commenced in April 2025.
• Continue the Phase 2 ADDRESS-LC study of bezisterim for Long COVID, which commenced in May 2025.
• Finalize the protocol design for the Phase 3 study of BIV201 for cirrhosis and ascites.
• Continue to pursue strategic plans to obtain sufficient financing to fund continuing operations.

Key Dates

Recommendation

Keywords

Biopharmaceutical, Clinical-stage, Alzheimer's Disease, Parkinson's Disease, Long COVID, Liver Cirrhosis, Ascites, Bezisterim, NE3107, BIV201, Terlipressin, SEC Filing, S-1/A, Public Offering, Warrants, Pre-funded Warrants, Clinical Trials, Drug Development, Neurodegenerative Disorders, Inflammation, Insulin Resistance, Orphan Drug, Fast Track, Intellectual Property, Going Concern, Litigation, Reverse Stock Split, Nasdaq